Takeda Pharmaceutical Company Limited (NYSE:TAK) Shares Acquired by Voloridge Investment Management LLC

Voloridge Investment Management LLC raised its stake in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK - Free Report) by 150.6% in the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 340,953 shares of the company's stock after buying an additional 204,911 shares during the period. Voloridge Investment Management LLC's holdings in Takeda Pharmaceutical were worth $4,514,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of the stock. First Trust Advisors LP raised its stake in shares of Takeda Pharmaceutical by 2.0% during the 4th quarter. First Trust Advisors LP now owns 3,240,932 shares of the company's stock valued at $42,910,000 after buying an additional 62,718 shares during the last quarter. Van ECK Associates Corp increased its stake in shares of Takeda Pharmaceutical by 1.6% in the 4th quarter. Van ECK Associates Corp now owns 2,210,428 shares of the company's stock valued at $29,266,000 after purchasing an additional 35,192 shares in the last quarter. Northern Trust Corp increased its stake in shares of Takeda Pharmaceutical by 14.6% in the 4th quarter. Northern Trust Corp now owns 1,873,588 shares of the company's stock valued at $24,806,000 after purchasing an additional 238,161 shares in the last quarter. Soleus Capital Management L.P. increased its stake in shares of Takeda Pharmaceutical by 136.0% in the 4th quarter. Soleus Capital Management L.P. now owns 1,180,000 shares of the company's stock valued at $15,623,000 after purchasing an additional 680,000 shares in the last quarter. Finally, Summit Global Investments increased its stake in shares of Takeda Pharmaceutical by 75.5% in the 4th quarter. Summit Global Investments now owns 729,200 shares of the company's stock valued at $9,655,000 after purchasing an additional 313,642 shares in the last quarter. Hedge funds and other institutional investors own 9.17% of the company's stock.

Analysts Set New Price Targets

Separately, Morgan Stanley upgraded Takeda Pharmaceutical from an "equal weight" rating to an "overweight" rating in a research note on Wednesday, April 2nd.

Takeda Pharmaceutical Price Performance

Shares of Takeda Pharmaceutical stock traded up $0.21 on Friday, hitting $15.01. 1,725,292 shares of the company were exchanged, compared to its average volume of 1,938,305. The stock has a market capitalization of $47.76 billion, a price-to-earnings ratio of 37.53, a price-to-earnings-growth ratio of 0.24 and a beta of 0.26. The company has a quick ratio of 0.72, a current ratio of 1.31 and a debt-to-equity ratio of 0.63. The company has a 50-day moving average price of $14.66 and a 200 day moving average price of $14.05. Takeda Pharmaceutical Company Limited has a 1-year low of $12.58 and a 1-year high of $15.43.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last announced its earnings results on Thursday, May 8th. The company reported $0.16 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.24 by ($0.08). Takeda Pharmaceutical had a net margin of 4.53% and a return on equity of 9.39%. The firm had revenue of $7.34 billion during the quarter, compared to analysts' expectations of $8.02 billion. As a group, sell-side analysts predict that Takeda Pharmaceutical Company Limited will post 1.64 earnings per share for the current fiscal year.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.